Lenvatinib Plus Pembrolizumab Sustain Efficacy After 4 Years in Patients With RCC
Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.
CAR T Cells Show Encouraging Early Responses in Relapsed/Refractory B-Cell NHL
A second-generation 4chimeric antigen receptor (CAR) T-cell agent has induced responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated in a phase 1 study.
An Updated Analysis of Pembrolizumab (MK-3475) for Melanoma
Jedd D. Wolchok, MD, PhD, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma.
Robust Antitumor Activity Seen With Pembrolizumab in PD-L1-Positive NSCLC
The anti-PD-1 humanized antibody pembrolizumab (MK-3475) has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive nonâ€“small cell lung cancer (NSCLC).
An Analysis of the PROCLAIM 2007-2012 National Registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry
BPX-201 Vaccine for Chemotherapy-NaÃ¯ve mCRPC
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncologyâ€“Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naÃ¯ve mCRPC.
Research into MPDL3280A for the Treatment of Lung Cancer
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
New Data on Immunotherapies for Head and Neck Cancers
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses new data on immunotherapies for head and neck cancers.
The Potentiation of Checkpoint Blockade With Oncolytic Virus
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
'Very, Very Impressive' Results Seen With Ipilimumab/Nivolumab Combination
Phase I results presented in 2013 from a study combining ipilimumab with the anti-PD-1 antibody, nivolumab,1 showed a 40% objective response rate in 53 patients with advanced melanoma and a preliminary overall survival (OS) of 80%.
T-VEC Shows Promise in Combinations and as Monotherapy in Unresectable Melanoma
The intratumoral injection talimogene laherparepvec (T-VEC) demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.
Pembrolizumab (MK-3475) Continues to Deliver Impressive Results in Melanoma
Pembrolizumab continues to deliver impressive results in patients with advanced melanomaâ€”producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
Adjuvant Ipilimumab Improves RFS by 25% in Stage III Melanoma
The immunotherapy drug ipilimumab (Yervoy) reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive (stage III) melanoma.
Immunotherapy Targeting HPV Demonstrates Activity in Cervical Cancer
Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV).
FDA Grants Breakthrough Therapy Designation to MPDL3280A for Bladder Cancer
MPDL3280A received the first Breakthrough Therapy Designation from the FDA for bladder cancer, according to information released May 31, 2014 at the 50th Annual Meeting of ASCO.
2 Commerce Drive Cranbury, NJ 08512